Tezspire Approved in EU for CRSwNP

TL;DR

EU approves AstraZeneca's Tezspire for nasal polyps, big win for the drug.

AI Summary

AstraZeneca PLC announced on October 22, 2025, that Tezspire has received European Union approval for the treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This approval follows positive clinical trial data and marks a significant expansion for the drug's therapeutic indications.

Why It Matters

This EU approval expands the market for Tezspire, potentially increasing revenue for AstraZeneca and offering a new treatment option for patients suffering from Chronic Rhinosinusitis with Nasal Polyps.

Risk Assessment

Risk Level: low — This filing is an informational report of a regulatory approval, which is generally positive news with low inherent risk.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Tezspire (drug) — Medication approved
• European Union (jurisdiction) — Regulatory body
• Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (medical condition) — Indication for approval
• October 2025 (date) — Reporting period

FAQ

From the Filing

0001654954-25-012040.txt : 20251022 0001654954-25-012040.hdr.sgml : 20251022 20251022080720 ACCESSION NUMBER: 0001654954-25-012040 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251022 FILED AS OF DATE: 20251022 DATE AS OF CHANGE: 20251022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251408640 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a2961e.htm TEZSPIRE APPROVED IN EU FOR CRSWNP a2961e FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Tezspire Approved in EU for CRSwNP     22 October 2025   Tezspire  approved in the EU for chronic rhinosinusitis with nasal polyps   Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic corticosteroid use vs. placebo   AstraZeneca and Amgen's  Tezspire  (tezepelumab) has been approved in the European Union (EU) as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to standard therapy (systemic corticosteroids and/or surgery).   The approval by the European Commission (EC) follows the  positive opinion  of the Committee for Medicinal Products for Human Use (CHMP) and was based on positive results from the  WAYPOINT  Phase III trial, presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress and simultaneously published in  The New England Journal of Medicine ​. 1-3  In the trial,  Tezspire  demonstrated a statistically significant and clinically meaningful reduction in nasal polyp severity ,  and showed near-elimination of the need for surgery and significant reduction in systemic corticosteroid use vs. placebo. 2,3   Dr. Oliver